Related Experiment Video
Updated: Jul 12, 2025

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
Enhanced External Counterpulsation for the Treatment of Angina With Nonobstructive Coronary Artery Disease
Namrita D Ashokprabhu1, Jessie Fox2, Timothy D Henry1
1Women's Heart Center, The Christ Hospital Heart and Vascular Institute, Cincinnati, Ohio; The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio.
Insights
Enhanced external counterpulsation (EECP) effectively treats refractory angina in patients with nonobstructive coronary artery disease (ANOCA). This noninvasive therapy significantly improves angina class, exercise capacity, and quality of life, offering a valuable treatment option.
Area of Science:
- Cardiology
- Vascular Medicine
- Noninvasive Cardiovascular Therapies
Background:
- Angina and nonobstructive coronary artery disease (ANOCA) presents challenges due to limited treatment options and poor outcomes.
- Enhanced external counterpulsation (EECP) is an established noninvasive therapy for refractory angina in obstructive coronary artery disease, but its role in ANOCA is less defined.
Purpose of the Study:
- To assess the efficacy of EECP in patients suffering from refractory angina despite having nonobstructive coronary artery disease (ANOCA).
- To evaluate the impact of EECP on Canadian Cardiovascular Society (CCS) angina class, exercise tolerance, and quality of life in ANOCA patients.
Main Methods:
- A cohort of 101 patients with ANOCA and CCS class III/IV angina underwent a full course of EECP treatment.
- Outcomes were measured by changes in CCS angina class, 6-minute walk test, Duke Activity Status Index (DASI), Seattle Angina Questionnaire 7 (SAQ7), and weekly anginal episodes pre- and post-treatment.
Main Results:
- Significant improvements were observed in CCS angina class (3.4 to 2.4, p <0.001), 6-minute walk test (p <0.001), DASI (15.2 to 31.5, p <0.001), SAQ7 (p <0.001), and weekly anginal episodes (5.3 to 2.4, p <0.001).
- Over 70% of patients experienced an improvement of at least one CCS angina class, with nearly 33% improving by two or more classes.
Conclusions:
- EECP therapy demonstrates significant benefits for patients with ANOCA experiencing refractory angina.
- The findings suggest EECP should be considered a valuable component of optimal medical therapy for this patient population, improving symptoms and functional capacity.
Abstract:
Angina and nonobstructive coronary artery disease (ANOCA) is associated with poor outcomes and limited treatment options. Enhanced external counterpulsation (EECP) is a noninvasive treatment that involves applying external inflatable cuffs to the lower extremities to increase blood flow during diastole, followed by deflation during systole. Although EECP is approved for treatment in patients with refractory angina due to obstructive coronary artery disease, its effectiveness in treating patients with ANOCA with refractory angina is limited to small studies. We assessed the efficacy of EECP treatment in patients with ANOCA (defined as ≤50% stenosis in any major epicardial vessels) with refractory anginaby measuring changes in Canadian Cardiovascular Society (CCS) angina class, 6-minute walk test, Duke Activity Status Index (DASI), Seattle Angina Questionnaire 7 (SAQ7), and weekly anginal episodes pre-EECP and post-EECP treatment. A total of 101 patients with ANOCA with CCS class III/IV angina completed a full course of EECP treatment at 2 large EECP centers. In 101 patients with ANOCA the mean age (SD) of 60.6 (11.3) years and 62.4% of the cohort were women. We found significant improvements post-EECP treatment in CCS angina class (mean (SD) 3.4 (0.5) to 2.4 (2.9), p <0.001), 6-minute walk test (median 1200 (IQR 972 to 1411) to 1358 (1170 to 1600), p <0.001), DASI (mean (SD) 15.2 (11.6) to 31.5 (16.3), p <0.001), SAQ7 (mean (DS) 36.2 (24.7) to 31.5 (16.3), p <0.001), and weekly anginal episodes (mean (SD) 5.3 (3.5) to 2.4 (2.9), p <0.001). After EECP treatment, 71 patients (70.3%) had an improvement of ≥1 CCS angina class, including 33 (32.7%) patients improving by ≥2 CCS classes. In conclusion, in patients with ANOCA, EECP therapy reduces CCS angina class and improves exercise tolerance and capacity; and should be considered a part of optimal medical therapy.
Related Concept Videos
Angina IV: Management
Angina V: Nursing Management
Coronary Artery Disease V: Interprofessional Care
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Angina II: Classification
Angina III: Clinical Manifestations and Assessment

